EGFR Assay Portfolio Service
Supported by in-house scientists and first-in-class technological platform, Creative Biolabs is confident in providing a series of EGFR assay services to facilitate your project success.
EGFR as a Key Target in Oncology
EGFR (also known as ERBB1 or HER1) is a transmembrane receptor tyrosine kinase (RTK) belonging to the ERBB-family, which includes EGFR/ ERBB1, HER-2/ ERBB2, HER-3/ ERBB4 and HER-4/ ERBB4. The ERBB receptors play a vital role in the development and growth of cells and tissues. Usually, the activation of EGFR by formation homo or heterodimer with another EGFR molecule, or a different member of the ERBB family (e.g., HER-2). The binding of EGFR ligands to the extracellular domain of EGFR will lead to receptor activation and stimulate downstream signaling pathways, which are crucial for cell proliferation and growth.
Aberrant activation of EGFR will ultimately lead to uncontrolled proliferation, which is also a hallmark of cancer cells. In addition, EGFR overexpressed or abnormal regulation of EGFR activation in cells may reduce apoptosis, enhance metastasis and even angiogenesis, which occurs in several human malignancies including breast cancer, non-small-cell lung cancer (NSCLC) and colorectal carcinoma (CRC).
Fig.1 EGFR-mediated signaling pathways and related therapy. (Zhao, 2017)
EGFR-Targeted Therapies
Clinically, the development and approval of EGFR-targeted therapy has been proven to be a promising strategy for EGFR-driven tumors over the past decades. Currently, there are two main classes of anti-EGFR drugs: small-molecule tyrosine kinase inhibitors (TKIs), which target the intracellular catalytic site of the EGFR; and monoclonal antibodies (mAbs), which target the extracellular domain blocking the dimerization of the receptor. What is more, increasing knowledge of EGFR biology has pushed more novel designs of combination therapies targeting EGFR, e.g., CAR-T therapy.
Fig.2 Approved EGFR-targeted drugs. (Creative Biolabs)
Our EGFR Assay Portfolio Services
Based on the advanced platforms and extensive experience in the field of immuno-oncology, Creative Biolabs is dedicated to providing a series of EGFR assay portfolio services with the highest quality standards. Our one-stop EGFR assay services include but are not limited to:
-
In vitro assays:
-
EGFR target validation and related analysis
-
Binding affinity test
-
Epitope mapping
-
Functional assay
-
In vivo assays:
-
Model construction
-
PK/PD study
If you are interested in our services, please do not hesitate to contact us for more detailed information. We are always pleased to help customers quickly and easily.
References
-
Guardiola, S.; et al. A third shot at EGFR: new opportunities in cancer therapy. Trends in pharmacological sciences. 2019, 40(12): 941-55.
-
Zhao, B.; et al. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget. 2017, 8(3): 3980.
For Research Use Only | Not For Clinical Use
Download our brochure